BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 19246139)

  • 1. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders.
    Valent P
    Blood Rev; 2009 Jul; 23(4):157-65. PubMed ID: 19246139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
    Gotlib J; Cross NC; Gilliland DG
    Best Pract Res Clin Haematol; 2006; 19(3):535-69. PubMed ID: 16781488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eosinophilic myeloid disorders.
    Noel P
    Semin Hematol; 2012 Apr; 49(2):120-7. PubMed ID: 22449622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular alterations underlying eosinophilic and mast cell malignancies.
    Sadrzadeh H; Abdel-Wahab O; Fathi AT
    Discov Med; 2011 Dec; 12(67):481-93. PubMed ID: 22204765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversies and open questions in the definitions and classification of the hypereosinophilic syndromes and eosinophilic leukemias.
    Valent P; Horny HP; Bochner BS; Haferlach T; Reiter A
    Semin Hematol; 2012 Apr; 49(2):171-81. PubMed ID: 22449627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
    Tefferi A; Thiele J; Vardiman JW
    Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypereosinophilic syndromes.
    Roufosse FE; Goldman M; Cogan E
    Orphanet J Rare Dis; 2007 Sep; 2():37. PubMed ID: 17848188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome.
    Bain BJ
    Br J Haematol; 1996 Oct; 95(1):2-9. PubMed ID: 8857931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia].
    Chrobák L; Voglová J
    Vnitr Lek; 2005 Dec; 51(12):1385-93. PubMed ID: 16430106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eosinophilic disorders.
    Simon D; Simon HU
    J Allergy Clin Immunol; 2007 Jun; 119(6):1291-300; quiz 1301-2. PubMed ID: 17399779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
    Tefferi A; Gotlib J; Pardanani A
    Mayo Clin Proc; 2010 Feb; 85(2):158-64. PubMed ID: 20053713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment.
    Tefferi A
    Mayo Clin Proc; 2005 Jan; 80(1):75-83. PubMed ID: 15667033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.
    Kelemen K; Saft L; Craig FE; Orazi A; Nakashima M; Wertheim GB; George TI; Horny HP; King RL; Quintanilla-Martinez L; Wang SA; Rimsza LM; Reichard KK
    Am J Clin Pathol; 2021 Feb; 155(2):179-210. PubMed ID: 33367563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance.
    Böhm A; Födinger M; Wimazal F; Haas OA; Mayerhofer M; Sperr WR; Esterbauer H; Valent P
    J Allergy Clin Immunol; 2007 Jul; 120(1):192-9. PubMed ID: 17451799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.